DOI QR코드

DOI QR Code

Outcomes of Malignant Ovarian Germ-Cell Tumors Treated in Chiang Mai University Hospital over a Nine Year Period

  • Neeyalavira, Vithida (Division of Gynecologic Oncology, Department of Obstetrics and Gynecology. Faculty of Medicine, Chiang Mai University) ;
  • Suprasert, Prapaporn (Division of Gynecologic Oncology, Department of Obstetrics and Gynecology. Faculty of Medicine, Chiang Mai University)
  • Published : 2014.06.30

Abstract

Malignant ovarian germ cell tumors (MOGCT) are rare neoplasms that most frequently occur in women at a young reproductive age. There have been limited data regarding this disease from Southeast Asian countries. We therefore conducted a retrospective study to analyze the clinical characteristics and the treatment outcomes of MOGCT treated at our institute between January, 2003 and December, 2012. Seventy-six patients were recruited from this period with the mean age of 21.6 years and 11.8% were pre-puberty. The two most common symptoms were pelvic mass and pelvic pain. Two-thirds of the studied patients presented at an early stage. The most common histology was immature teratoma (34.2%) followed by endodermal sinus tumor (28.9%), dysgerminoma (25%), mixed type (10.5%) and choriocarcinoma (1.3%). Over 80% of these patients received fertility sparing surgery and about 70% received adjuvant chemotherapy with the complete response rate at 73.3% and partial response at 11.1%. The most frequent chemotherapy was BEP regimen (bleomycin, etoposide, cisplatin). With the mean follow up time at 56.0 months, 12 patients (15.8%) developed recurrence and only an advanced stage was the independent prognostic factor. The ten year progression free survival (PFS) and overall survival rate of our study were 81.9% and 86.2%, respectively. In conclusion, MOGCT often occurs at a young age. Treatment with fertility sparing operations and adjuvant chemotherapy with a BEP regimen showed a good outcome. An advanced stage is a significant prognostic factor for recurrence.

References

  1. Patterson DM, Murugaesu N, Holden L, et al (2008). A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. Int J Gynecol Cancer, 18, 43-50. https://doi.org/10.1111/j.1525-1438.2007.00969.x
  2. Mahdi H, Swensen RE, Hanna R, et al (2011). Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. Br J Cancer, 105, 493-7. https://doi.org/10.1038/bjc.2011.267
  3. Mangili G, Sigismondi C, Gadducci A, et al (2011). Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study. Int J Gynecol Cancer, 21, 1414-21. https://doi.org/10.1097/IGC.0b013e3182236582
  4. Parkinson CA, Hatcher HM, Ajithkumar TV (2011). Management of malignant ovarian germ cell tumors. Obstet Gynecol Surv, 66, 507-14. https://doi.org/10.1097/OGX.0b013e318234ede9
  5. Solheim O, Kaern J, Trope CG, et al (2013). Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009). Gynecol Oncol, 131, 330-5. https://doi.org/10.1016/j.ygyno.2013.08.028
  6. Vazquer I, Rustin GJ (2013). Current controversies in the management of germ cell ovarian tumours. Curr Opin Oncol, 25, 539-45. https://doi.org/10.1097/01.cco.0000432609.39293.77
  7. Weinberg LE, Lurain JR, Singh DK, et al (2011). Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors. Gynecol Oncol, 121, 285-9. https://doi.org/10.1016/j.ygyno.2011.01.003
  8. Gershensom DM (2012). Treatment of ovarian cancer in young women. Clin Obstet Gynecol, 55, 65-74. https://doi.org/10.1097/GRF.0b013e318248045b
  9. Bilici A1, Inanc M, Ulas A, et al (2013). Clinical and pathologic features of patients with rare ovarian tumors: multi-center review of 167 patients by the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev, 14, 6439-9. https://doi.org/10.7314/APJCP.2013.14.11.6493
  10. Bhurgri Y1, Shaheen Y, Kayani N, et al (2011). Incidence, trends and morphology of ovarian cancer in Karachi (1995-2002). Asian Pac J Cancer Prev, 12, 1567-71.
  11. Billmire D, Vinocur C, Rescorla F, et al (2004). Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg, 39, 424-9. https://doi.org/10.1016/j.jpedsurg.2003.11.027
  12. Low JJ, IIancheran A, Ng JS (2012). Malignant ovarian germ-cell tumours. Best Pract Res Clin Obstet Gynaecol, 26, 347-55. https://doi.org/10.1016/j.bpobgyn.2012.01.002
  13. Matei D, Brown J, Frazier L (2013) . Updates in the management of ovarian germ cell tumors. Am Soc Clin Oncol Educ Book, 210-6.

Cited by

  1. Prognosis of Eight Chinese Cases of Primary Vaginal Yolk Sac Tumor with a Review of the Literature vol.15, pp.21, 2014, https://doi.org/10.7314/APJCP.2014.15.21.9395
  2. 8-year Analysis of the Prevalence of Lymph Nodes Metastasis, Oncologic and Pregnancy Outcomes in Apparent Early-Stage Malignant Ovarian Germ Cell Tumors vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1609
  3. Chemotherapy-induced acute psychosis in a patient with malignant germ cell tumour vol.2015, pp.apr09 1, 2015, https://doi.org/10.1136/bcr-2014-208982
  4. Ovarian Cancer in Young Women vol.8, pp.4, 2017, https://doi.org/10.1007/s13193-017-0680-z